CTLA-4: Negative Regulator of the Immune Response and a Target for Cancer Therapy
- 1 June 2008
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Immunotherapy
- Vol. 31 (5), 431-439
- https://doi.org/10.1097/cji.0b013e318174a4fe
Abstract
A novel approach for cancer immunotherapy is to augment T-cell-mediated immunity by blocking inhibitory signals that suppress T-cell function. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a key negative regulator of T-cell activation. CTLA-4 blockade using anti-CTLA-4 monoclonal antibodies (mAbs) potentiates the T-cell response against tumors, and preliminary data on these agents demonstrate good efficacy and tolerability in the treatment of patients with metastatic melanoma and other cancers. This paper will review data from studies with anti-CTLA-4 mAbs to date, discuss some of the key clinical considerations emerging from early clinical trials with this therapeutic strategy, and provide an overview of ongoing and planned clinical trials for anti-CTLA-4 mAb therapy in metastatic melanoma and other cancers.Keywords
This publication has 46 references indexed in Scilit:
- Management of Metastatic Melanoma 2005Surgical Oncology Clinics of North America, 2006
- Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trialThe Lancet, 2005
- Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant MelanomaJournal of Clinical Oncology, 2004
- Does Adjuvant Systemic Therapy with Interferon-?? for Stage II???III Melanoma Prolong Survival?American Journal of Clinical Dermatology, 2003
- Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trialThe Lancet, 2001
- Adjuvant interferon alpha 2b in high risk melanoma – the Scottish studyBritish Journal of Cancer, 2001
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993Journal of Clinical Oncology, 1999
- Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastasesThe Lancet, 1998
- Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.Journal of Clinical Oncology, 1998
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996